At a glance
ClinicalIndex Comparison RecordN/ACompleted· 1,715 enrolled
Drug / intervention
Etanerceptdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Observational Study Of The Use Of Enbrel (Registered) (Etanercept) In Routine Clinical Practice To Treat Ankylosing Spondylitis (as) Patients: An Effectiveness, Safety, And Health Economic Evaluation
In Brief
An observational study evaluating Etanercept for Ankylosing Spondylitis. Completed, enrolled 1,715 participants across 1 site.
Detailed Summary
This study aims to provide a holistic assessment of patients receiving etanercept in a real-world setting.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAnkylosing Spondylitis
CountriesGermany
Collaborators--
Timeline
N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartOct 2007
First PostedOct 2007
Primary CompletionMay 2014
TodayJul 2026
First PostedOct 16, 2007
Enrollment StartOct 1, 2007
Primary CompletionMay 1, 2014
TodayJul 2, 2026
Enrollment to primary: 6.6 yearsPosted 18.7 years ago
Interventions
Etanerceptdrug
The patients will be treated in accordance with the requirements of the labeling of etanercept in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.